befotertinib
Showing 1 - 1 of 1
NSCLC Trial in Xiamen (Icotinib, Befotertinib)
Recruiting
- Non-Small Cell Lung Cancer
- Icotinib
- Befotertinib
-
Xiamen, Fujian, ChinaFeng Ye
Sep 17, 2021